Into a vial was added the 4-bromo-2-fluoro-N-thiazol-2-yl-benzenesulfonamide (50 mg, 0.0001 mol), sodium tert-butoxide (43 mg, 0.00044 mol), 9,9-dimethyl-4,5-bis(diphenylphosphino)xanthene (1.0E1 mg, 0.000018 mol), tris(dibenzylideneacetone)dipalladium(0) (5.4 mg, 0.0000059 mol), 2-amino-4-(4-chlorophenyl)thiazole and the de-gassed anhydrous 1,4-dioxane (2.0 mL, 0.026 mol). The reaction mixture was heated at 150° C. for 1 h in microwave. The reaction mixture was filtered through celite and the filtrate was concentrated. The residue was diluted with EtOAc and washed with 1.0 N HCl, dried and was concentrated to give the crude product that was purified using Gilson preparative HPLC (reverse phase, Phenomenex 250×30 mm, 15 micron C18 column, 40 mL/min. Gradient, 85% A to 100% B over 25 min. Solvent A: 7800 water/200 acetonitrile/8 TFA. Solvent B: 7200 acetonitrile/800 water/8). Fractions were checked by LC/MS, then combined, and dried on a lyophilizer to give the product as a yellow solid (24.5 mg, 40%).
